Valuation: BriaCell Therapeutics Corp.

Market Cap 29.89M 26.82M 24.79M 22.46M 41.95M 2.85B 42.46M 296M 118M 1.49B 112M 110M 4.73B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 12.02M 10.79M 9.97M 9.03M 16.88M 1.15B 17.08M 119M 47.5M 599M 45.12M 44.17M 1.9B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.96%
Yield 2024 *
-
Yield 2025 -
10-28 BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2026 CI
10-23 Briacell Therapeutics Corp. Announces Clinical Biomarker Findings from Prospective Pooled Analysis of Patients with Metastatic Breast Cancer Treated with Immune Based Therapies Including the Briacell Regimen CI
09-14 BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor CI
09-11 Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer CI
09-08 BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center CI
09-02 Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-02 Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-02 Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-02 Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-02 Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
08-24 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+ CI
08-05 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study MT
08-05 Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer CI
1 day-2.99%
1 week-4.33%
Current month-20.33%
1 month-15.18%
6 months-11.96%
Current year-50.41%
1 week 4.72
Extreme 4.72
5.1
1 month 4.72
Extreme 4.72
6.15
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
18
3 years 3.68
Extreme 3.68
1,200
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 01/11/2016
Director of Finance/CFO 54 01/02/2016
Chief Tech/Sci/R&D Officer 65 16/02/2022
Director TitleAgeSince
Director/Board Member 70 01/11/2016
Chairman 41 24/04/2019
Director/Board Member 74 07/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 A Tax

Director

45,000 0.5173%
7/7/26 A Tax

Director

15,000 0.1724%
7/7/26 A Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-2.99%-4.33%-73.94%-99.38% 30.12M
+0.65%-3.36%+36.98%+60.50% 64.14B
+1.03%+2.73%+12.31%+84.00% 55.53B
+1.19%+1.81%+13.08%+105.33% 53.03B
+2.76%+0.87%+27.92%+55.07% 45.99B
+2.00%-3.39%+17.83%+119.04% 42.45B
+1.34%-2.86%+224.43%+914.08% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
-2.26%+42.16%+102.96%+89.50% 34.47B
-2.72%-0.44%+23.18%-10.77% 24.23B
Average +0.17%+3.24%+39.59%+136.29% 39.26B
Weighted average by Cap. +0.78%+3.49%+49.26%+160.43%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.3M -3.97M -3.6M -6.72M -456M -6.81M -47.52M -18.93M -239M -17.98M -17.6M -758M -26.31M -23.61M -21.83M -19.77M -36.93M -2.51B -37.38M -261M -104M -1.31B -98.74M -96.65M -4.16B
Net Debt -862K -773K -715K -648K -1.21M -82.11M -1.22M -8.55M -3.41M -42.96M -3.24M -3.17M -136M -17.87M -16.03M -14.82M -13.42M -25.08M -1.7B -25.38M -177M -70.58M -890M -67.05M -65.63M -2.83B
Projected Income Statement - Annual - BriaCell Therapeutics Corp.
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
28/10/26 CA$4.860 -2.99% 2,012
27/10/26 CA$5.010 +2.87% 4,150
26/10/26 CA$4.870 +1.67% 4,182
23/10/26 CA$4.790 -1.03% 1,187
22/10/26 CA$4.840 -4.72% 4,398

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BriaCell Therapeutics Corp.